1. Home
  2. CTNM vs CRNC Comparison

CTNM vs CRNC Comparison

Compare CTNM & CRNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • CRNC
  • Stock Information
  • Founded
  • CTNM 2009
  • CRNC 2020
  • Country
  • CTNM United States
  • CRNC United States
  • Employees
  • CTNM N/A
  • CRNC N/A
  • Industry
  • CTNM
  • CRNC EDP Services
  • Sector
  • CTNM
  • CRNC Technology
  • Exchange
  • CTNM Nasdaq
  • CRNC Nasdaq
  • Market Cap
  • CTNM 328.1M
  • CRNC 362.2M
  • IPO Year
  • CTNM 2024
  • CRNC N/A
  • Fundamental
  • Price
  • CTNM $10.93
  • CRNC $10.44
  • Analyst Decision
  • CTNM Strong Buy
  • CRNC Hold
  • Analyst Count
  • CTNM 5
  • CRNC 5
  • Target Price
  • CTNM $20.40
  • CRNC $10.40
  • AVG Volume (30 Days)
  • CTNM 166.5K
  • CRNC 1.9M
  • Earning Date
  • CTNM 10-30-2025
  • CRNC 11-19-2025
  • Dividend Yield
  • CTNM N/A
  • CRNC N/A
  • EPS Growth
  • CTNM N/A
  • CRNC N/A
  • EPS
  • CTNM N/A
  • CRNC N/A
  • Revenue
  • CTNM N/A
  • CRNC $251,781,000.00
  • Revenue This Year
  • CTNM N/A
  • CRNC $4.51
  • Revenue Next Year
  • CTNM N/A
  • CRNC N/A
  • P/E Ratio
  • CTNM N/A
  • CRNC N/A
  • Revenue Growth
  • CTNM N/A
  • CRNC N/A
  • 52 Week Low
  • CTNM $3.35
  • CRNC $3.39
  • 52 Week High
  • CTNM $16.25
  • CRNC $27.50
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 47.95
  • CRNC 53.89
  • Support Level
  • CTNM $10.46
  • CRNC $7.60
  • Resistance Level
  • CTNM $13.09
  • CRNC $12.02
  • Average True Range (ATR)
  • CTNM 0.98
  • CRNC 0.70
  • MACD
  • CTNM 0.08
  • CRNC 0.10
  • Stochastic Oscillator
  • CTNM 29.68
  • CRNC 62.67

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About CRNC Cerence Inc.

Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.

Share on Social Networks: